湖南九典制药股份有限公司 投资者关系活动记录表 编号：2025-20 | | 特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | 类别 | □现场参观 其他 2025 年半年度业绩说明电话 | | | 会议 | | 参与单位名称及 | 平安证券、开源证券、华安证券、国盛证券、中信证券、东 | | 人员姓名 | 北证券、天风证券、华源证券等机构投资者代表及个人投资 | | | 者共 75 人 | | | 2025 年 8 月 24 日晚上 20:00-21:00 | | 时间 | 2025 年 8 月 25 日上午 10:00-11:00 | | 地点 | 公司会议室 | | | 董事、总经理：杨洋 | | 上市公司接待人 | 副总经理兼董事会秘书：曾蕾 | | 员姓名 | 财务总监：熊英 | | | 研究院院长：肖稳定 | | | 首先董事会秘书介绍了公司 2025 年半年度的经营情况： | | | 2025 年上半年公司实现营业收入 15.12 亿元，同比增长 | | | 10.67%；归属上市公司股 ...

Core Viewpoint - The company, Jiutian Pharmaceutical, is actively engaged in the research, development, and sales of pharmaceutical products, with a focus on expanding its product offerings and market presence through innovation and internationalization efforts [1][8]. Group 1: Product Development and Market Strategy - Jiutian Pharmaceutical is currently in the information reporting phase for the 11th batch of centralized procurement for its drug, Loxoprofen Sodium Gel Patch, and cannot estimate the price reduction at this stage [2]. - The company has six external preparations already on the market and expects to gain approval for additional products, including Indomethacin Gel Patch and Flurbiprofen Gel Patch, by 2025, with further products anticipated in 2026 [3]. - The company has developed a new sales strategy for Ketoprofen Gel Patch, which was approved in 2023 and has entered the national medical insurance directory, focusing on increasing resources for the outpatient market and enhancing internal sales team assessments [5]. Group 2: International Expansion and Innovation - Jiutian Pharmaceutical has made progress in exporting its formulations, having developed 46 international clients, with successful exports to Ecuador and preparations for registration in Costa Rica [4]. - The company is also focusing on innovation, with a new product, Pepper Seven Pain Relief Gel Patch, classified as a Class 1 innovative drug, and has entered into a technology transfer agreement for antimicrobial peptides to enhance its drug development capabilities [6]. Group 3: Financial Performance and R&D Investment - In the first quarter of 2025, Jiutian Pharmaceutical reported a main revenue of 696 million yuan, a year-on-year increase of 17.79%, and a net profit of 126 million yuan, reflecting a slight increase of 0.08% [8]. - The company plans to invest 261 million yuan in R&D in 2024, which represents 8.91% of its operating income, and aims to maintain this investment ratio to ensure continuous output and enhance its competitive edge [7]. Group 4: Earnings Forecast - Recent earnings forecasts indicate that Jiutian Pharmaceutical's net profit is expected to reach approximately 677 million yuan in 2025, with projections of 775 million yuan in 2026 and further growth anticipated in 2027 [11].

Group 1: Investor Relations Activity - The investor relations activity involved a meeting with representatives from Taikang Asset and China Post Securities, held on July 30, 2025 [2] - The meeting was led by the Deputy General Manager and Board Secretary, Zeng Lei, along with the Securities Affairs Representative, Gan Rong [2] Group 2: Product Development and Market Strategy - The company is currently in the information reporting stage for the collection of the eleventh batch of the drug Loxoprofen Sodium Gel Patch, with no specific price reduction estimates available yet [2] - The company has six external preparations already on the market and expects to gain approval for additional products, including Indomethacin Gel Patch and Flurbiprofen Gel Patch in 2025, and Ketoprofen Patch and others in 2026 [2][3] - The company has made progress in export development, with 46 clients engaged, including successful exports of Nitazoxanide Tablets to Ecuador and preparations for the registration of Ketoprofen Gel in Costa Rica [4] Group 3: Sales Expectations and Brand Strategy - The Ketoprofen Gel Patch was approved for market entry in 2023 and is included in the national medical insurance directory, with optimistic market prospects and a new sales strategy focusing on outpatient markets [5] - The company aims to strengthen its internal sales team assessments to enhance the "Jiu Yue" brand of patches [5] Group 4: Innovation and R&D Investment - The company is developing a Class 1 innovative drug, Pepper Seven Pain Relief Gel Patch, and has entered into a technology transfer agreement for antibacterial and anti-inflammatory peptides [6] - In 2024, the company plans to invest CNY 261 million in R&D, representing 8.91% of its revenue, with a commitment to maintain this investment ratio for sustained innovation and market competitiveness [7]

Group 1: Product Information - The price of Loxoprofen Sodium Gel Patch in local procurement is approximately [2] - The company believes that Loxoprofen Sodium Gel Patch and Ketoprofen Gel Patch complement each other in the market and do not compete directly [2] - Currently, the Loxoprofen Sodium Gel Patch is in the information submission phase for the 11th batch of centralized procurement [3] Group 2: R&D and Product Development - The company has six external preparations already on the market, including Loxoprofen Sodium Gel Patch and Ketoprofen Gel Patch [3] - Expected approvals in 2025 include Indomethacin Gel Patch and Flurbiprofen Gel Patch, while approvals in 2026 are anticipated for Ketoprofen Patch and others [3] Group 3: Marketing Strategy - The company focuses on continuous R&D investment to enrich its product matrix and leverage first-mover, scale, and cost advantages [3] Group 4: Financial Outlook - The company projects a revenue growth of 10-20% for 2025, with a similar expected increase in net profit [3] - There are risks associated with achieving these targets due to market conditions and industry policies, which may lead to uncertainties in forecasts [3]

Group 1: Company Advantages - The company has a complete industrial chain layout, allowing it to independently produce active pharmaceutical ingredients and key excipients, ensuring product quality while effectively controlling costs [2] - A full-channel coverage system has been established, particularly in the outpatient market, which has become a new engine for revenue growth [2] - Continuous high investment in R&D to innovate and expand the product line, with a focus on strengthening the "JiuYue" brand in the transdermal drug delivery field [2] Group 2: Product Expectations and Market Strategy - The ketoprofen gel patch was approved for market in 2023 and has entered the national medical insurance directory, being the first generic product in the domestic market [3] - The company is optimistic about the market prospects for the ketoprofen gel patch and has developed new sales strategies focusing on outpatient market resources and internal sales team assessments [3] Group 3: Financial Projections - The company expects a revenue growth of 10-20% year-on-year for 2025, with a similar growth forecast for net profit excluding non-recurring items [4] - There are risks associated with achieving these targets due to market conditions, operational environment, and industry policies, which may introduce significant uncertainties [4] Group 4: Product Development Progress - The indomethacin gel patch is currently undergoing supplementary data review, while the pepper and musk gel patch has completed supplementary research and is awaiting registration application [5] - Differences between the loxoprofen sodium gel patch and the anti-inflammatory plaster include active ingredients, indications, and prescription attributes, with loxoprofen being a prescription drug for musculoskeletal pain [6]

Core Viewpoint - The report provides a comprehensive analysis of the financial status, operational performance, and market conditions of the company, focusing on its recent developments and future outlook in the pharmaceutical industry. Financial Data and Indicators - The company's cash and cash equivalents are projected to increase from 2.93 billion yuan in 2022 to 4.94 billion yuan by the end of 2024, indicating a growth trend [3] - The total assets are expected to rise from 23.00 billion yuan in 2022 to 34.89 billion yuan by the end of 2024, reflecting a strong asset base [3] - The net profit is forecasted to grow from 2.70 billion yuan in 2022 to 5.12 billion yuan in 2024, showcasing significant profitability [4] - The operating cash flow is anticipated to increase from 1.92 billion yuan in 2022 to 6.13 billion yuan by 2024, indicating improved cash generation capabilities [3] Business Operations - The company focuses on the research, production, and sales of pharmaceutical products, with a core revenue source from drug formulations, accounting for over 80% of its core business income [8][9] - The main products include pain relief and digestive system medications, with significant sales growth in OTC channels and online markets [10][11] - The company has expanded its production capacity, with a new high-end formulation research and development park completed in March 2023, enhancing its production capabilities for key products [12] Market Conditions - The pharmaceutical industry is facing challenges from price control policies and increased competition, leading to a slight decline in profit margins [7][8] - Despite short-term pressures, the long-term outlook for the industry remains positive due to factors such as aging population and rising health awareness, which are expected to drive demand [7][8] - The company has successfully participated in multiple provincial-level centralized procurement projects, which has increased sales volume but also led to a decrease in sales prices due to competitive bidding [14] Future Outlook - The company plans to invest in additional production lines for raw materials and pharmaceutical excipients, with ongoing projects expected to enhance production capacity significantly by 2026 [12][13] - The anticipated increase in production capacity and ongoing market expansion efforts are expected to support revenue growth in the coming years, despite current market challenges [10][11]

Group 1: Company Strategy and Market Positioning - The company is focusing on three key areas for future strategic planning: expanding sales channels, increasing R&D efforts, and optimizing production processes to enhance operational efficiency and shareholder value [2] - The company aims to strengthen its presence in the outpatient market while enhancing brand influence, particularly for the "JiuYue" transdermal patch brand [3] - The company plans to launch several transdermal products, including Lidocaine Gel Patch and Indomethacin Gel Patch, expected to be approved in 2025, and Ketoprofen Patch and Flurbiprofen Patch in 2026 [4] Group 2: Product Development and Competition - The company believes that the market for external anti-inflammatory drugs is currently underserved, and the two products, Loxoprofen Sodium Gel Patch and Ketoprofen Gel Patch, will complement each other rather than compete [7] - The Loxoprofen Sodium Gel Patch has a high drug loading of 100mg per patch and is suitable for a wide range of conditions, while the Ketoprofen Gel Patch offers better drug permeability and efficacy for osteoarthritis [5] Group 3: Financial Projections and Market Risks - The company projects a revenue growth of 10-20% for the fiscal year 2025, with a similar expectation for net profit excluding non-recurring items [11][12] - The company acknowledges that its operational plans and product sales depend on various factors, including market conditions and industry policies, which introduce significant uncertainty [12] Group 4: Cost Management and Procurement Strategy - The company plans to reduce sales expenses by optimizing marketing strategies and expanding outpatient market reach [2] - The company maintains an integrated development strategy for raw materials and finished products, ensuring quality control and cost management through in-house production [10]

Investment Rating - The report maintains a "Recommend" rating for the company, indicating an expectation that the stock will outperform the market by 10% to 20% over the next six months [12]. Core Insights - The company achieved a revenue of 2.931 billion yuan in 2024, representing a year-on-year growth of 8.85%, while the net profit increased by 39.13% to 512 million yuan [3][7]. - The improvement in the sales expense ratio, which decreased by 6.29 percentage points to 42.27%, significantly contributed to the higher profit growth compared to revenue growth [7]. - The company’s core product, the Loxoprofen Sodium Gel Patch, saw a substantial increase in sales, with a 25.65% growth in the hospital market and a remarkable 173.79% growth in the outpatient market [7]. - The company is expanding its product line with new external preparations, enhancing its long-term competitive edge [7]. Financial Summary - The company’s total assets are projected to grow from 3.373 billion yuan in 2024 to 5.201 billion yuan by 2027, with a steady increase in current assets [9]. - The net profit forecast for 2025 and 2026 has been adjusted to 600 million yuan and 746 million yuan, respectively, reflecting a strong growth trajectory [8]. - The earnings per share (EPS) is expected to rise from 1.03 yuan in 2024 to 1.83 yuan by 2027, indicating a positive outlook for shareholder returns [10]. Revenue and Profitability Projections - Revenue is expected to grow from 2.931 billion yuan in 2024 to 4.804 billion yuan by 2027, with a compound annual growth rate (CAGR) of approximately 16.3% [10]. - The gross margin is projected to remain stable around 73.9% to 74.0% over the forecast period, indicating strong cost control [10]. - The return on equity (ROE) is anticipated to improve from 20.3% in 2024 to 21.0% by 2027, reflecting enhanced profitability [10].

Company Overview - The company is a modern listed pharmaceutical enterprise that integrates research and development, production, sales, and CXO services across various fields including chemical drug formulations, active pharmaceutical ingredients, pharmaceutical excipients, traditional Chinese medicine, and health products [5][6]. Industry Development - The biopharmaceutical industry in China has experienced rapid growth over the past decade, supported by new government policies aimed at fostering innovation across the entire value chain [7]. - In 2024, the government proposed a health-first development strategy, promoting the coordinated development of healthcare, medical insurance, and pharmaceuticals [7]. - The pharmaceutical manufacturing industry achieved a revenue of 2,529.85 billion yuan in 2024, with a profit total of 342.07 billion yuan, indicating a slight decline in profitability due to cost pressures [8]. Market Competition - The pharmaceutical industry is undergoing rapid transformation, shifting focus from traditional disease treatment to preventive healthcare and comprehensive health management [9]. - The penetration of instant retail models and the application of digital technologies are enhancing the efficiency and convenience of pharmaceutical services [9]. - Despite global economic uncertainties, the market demand remains robust due to increasing health awareness and an aging population, supported by ongoing government investments in healthcare [9]. Company Position in the Industry - The company has seen a steady increase in sales of its main drug formulations, with products like Loxoprofen Sodium Gel and Pantoprazole Sodium Enteric-Coated Tablets performing well in the market [10]. - The company is recognized as one of the larger producers of chemical active pharmaceutical ingredients and excipients in China, with a strong brand reputation and market share [11]. - The company has a diverse portfolio of 87 registered active pharmaceutical ingredients, with 68 in A status, and is a major supplier of high-quality excipients for biological vaccines [11]. Financial Performance - The company received a standard unqualified audit opinion for its financial report, indicating a stable financial position [2]. - The board approved a profit distribution plan, proposing a cash dividend of 3.10 yuan per 10 shares, reflecting a commitment to returning value to shareholders [4].